Burgess, David S.
(College of Pharmacy, The University of Texas at Austin, Austin, TX, USA)
,
Hastings, Rhonda W.
(College of Pharmacy, The University of Texas at Austin, Austin, TX, USA)
,
Summers, Kimberly K.
(College of Pharmacy, The University of Texas at Austin, Austin, TX, USA)
,
Hardin, Thomas C.
(College of Pharmacy, The University of Texas at Austin, Austin, TX, USA)
,
Rinaldi, Michael G.
(Department of Pathology, the University of Texas Health Science Center at San Antonio, San Antonio, TX, USA)
AbstractThe objective of this study was to evaluate the pharmacodynamic activity of fluconazole, itraconazole, and amphotericin B against Candida albicans. Susceptibilities were determined according to the NCCLS guidelines (M27). Time-kill studies were performed using antifungal concentrations of 0....
AbstractThe objective of this study was to evaluate the pharmacodynamic activity of fluconazole, itraconazole, and amphotericin B against Candida albicans. Susceptibilities were determined according to the NCCLS guidelines (M27). Time-kill studies were performed using antifungal concentrations of 0.25–32 × MIC. Samples were withdrawn at predetermined timepoints, then plated using a spiral plater. Colony counts were determined after incubation at 35°C for 24 h. The AUKC0–48 was plotted against the concentration/MIC ratio. Candida isolates (95-2672, 96-15, and 95-2542) were classified as susceptible, susceptible-dose dependent, and resistant to fluconazole and itraconazole (MIC = 0.25 and 0.03 μg/mL, 32 and 0.5 μg/mL, 64 and 1 μg/mL; respectively). All three isolates were susceptible to amphotericin B (MIC = 0.13 μg/mL). Fluconazole inhibited the growth of the susceptible and S-DD isolates and was ineffective at all concentrations against the resistant isolate. Itraconazole, on the other hand, inhibited growth of the susceptible isolate, but was ineffective for the S-DD and resistant isolates. Maximal effectiveness was noted at the concentration 8 × MIC and 2 × MIC for fluconazole and itraconazole, respectively. Amphotericin B demonstrated concentration-dependent antifungal activity. The times necessary for the colony counts to fall below the limit of quantification were inversely related to increasing concentrations of amphotericin B. The maximal effect for amphotericin B was recorded at 2 × MIC. In summary, the triazoles inhibit growth of susceptible C. albicans; however, careful consideration should be given to the MIC for S-DD isolates because itraconazole may not be active if the MIC is reported in the higher susceptible-dose dependency range. In reference to amphotericin B, optimal activity may be achieved by maximizing the peak drug concentration/MIC ratio.
AbstractThe objective of this study was to evaluate the pharmacodynamic activity of fluconazole, itraconazole, and amphotericin B against Candida albicans. Susceptibilities were determined according to the NCCLS guidelines (M27). Time-kill studies were performed using antifungal concentrations of 0.25–32 × MIC. Samples were withdrawn at predetermined timepoints, then plated using a spiral plater. Colony counts were determined after incubation at 35°C for 24 h. The AUKC0–48 was plotted against the concentration/MIC ratio. Candida isolates (95-2672, 96-15, and 95-2542) were classified as susceptible, susceptible-dose dependent, and resistant to fluconazole and itraconazole (MIC = 0.25 and 0.03 μg/mL, 32 and 0.5 μg/mL, 64 and 1 μg/mL; respectively). All three isolates were susceptible to amphotericin B (MIC = 0.13 μg/mL). Fluconazole inhibited the growth of the susceptible and S-DD isolates and was ineffective at all concentrations against the resistant isolate. Itraconazole, on the other hand, inhibited growth of the susceptible isolate, but was ineffective for the S-DD and resistant isolates. Maximal effectiveness was noted at the concentration 8 × MIC and 2 × MIC for fluconazole and itraconazole, respectively. Amphotericin B demonstrated concentration-dependent antifungal activity. The times necessary for the colony counts to fall below the limit of quantification were inversely related to increasing concentrations of amphotericin B. The maximal effect for amphotericin B was recorded at 2 × MIC. In summary, the triazoles inhibit growth of susceptible C. albicans; however, careful consideration should be given to the MIC for S-DD isolates because itraconazole may not be active if the MIC is reported in the higher susceptible-dose dependency range. In reference to amphotericin B, optimal activity may be achieved by maximizing the peak drug concentration/MIC ratio.
참고문헌 (13)
Am J Med Banerjee 91 Suppl B 86S 1991 10.1016/0002-9343(91)90349-3 Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989
J Infect Dis Beck-Sague 167 1247 1993 10.1093/infdis/167.5.1247 Secular trends in the epidemology of nosocomial fungal infections in the United States, 1980-1990
ASM News Fox 59 515 1993 Fungal Infection Rates are Increasing
Clin Inf Dis Fraser 15 414 1992 10.1093/clind/15.3.414 Candidemia in a tertiary care hospital
Clin Inf Dis Guiot 18 525 1994 10.1093/clinids/18.4.525 Risk factors for fungal infection in patients with malignant hematologic disorders
Antimicrob Agents Chemother Klepser 41 1392 1997 10.1128/AAC.41.6.1392 Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
J Antimicrob Chemother Meunier 25 227 1990 10.1093/jac/25.2.227 In-vitro activity of SCH 39304 in comparison with amphotericin B and fluconazole
National Committee for Clinical Laboratory Standards. (1997). Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standards M27-T. Villanova, PA: National Committee for Clinical Laboratory Standards.
N Engl J Med Rex 331 1325 1994 10.1056/NEJM199411173312001 A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
※ AI-Helper는 부적절한 답변을 할 수 있습니다.